NPS Pharmaceuticals to Report Second Quarter 2012 Financial Results
BEDMINSTER, N.J.--(BUSINESS WIRE)-- NPS Pharmaceuticals, Inc. (NPSP) announced today that it will report its second quarter 2012 financial results on Wednesday, August 1, 2012 at approximately 4:30 p.m. ET. The press release will be followed by a conference call and webcast at 5:00 p.m. ET.
To participate in the conference call, dial (866) 730-5762 and use passcode 76762943. International callers may dial (857) 350-1586, using the same passcode. In addition, a live audio of the conference call will be available over the Internet. Interested parties can access the event through the investors calendar of events page on the NPS website, http://www.npsp.com/page/calendar.
If you are unable to participate in the live call, a replay will be available at (888) 286-8010, with passcode 81581902 until midnight ET, August 15, 2012. International callers may access the replay by dialing (617) 801-6888, using the same passcode. The webcast will also be available through the NPS website for the same period.
About NPS Pharmaceuticals
NPS Pharmaceuticals is a biopharmaceutical company focused on bringing orphan products to patients with rare disorders and few, if any, therapeutic options. NPS is advancing two late-stage registration programs. A New Drug Application is undergoing FDA review for Gattex® (teduglutide) as a treatment for adult short bowel syndrome (SBS) and a Phase 3 registration study has been completed for Natpara" (recombinant human parathyroid hormone (rhPTH [1-84]) in adult hypoparathyroidism. NPS' earlier stage pipeline includes two calcilytic compounds, NPSP790 and NPSP795, with potential application in rare disorders involving increased calcium receptor activity, such as autosomal dominant hypocalcemia with hypercalciuria (ADHH). NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, GlaxoSmithKline, Janssen Pharmaceuticals, Kyowa Hakko Kirin, and Nycomed (acquired by Takeda Pharmaceutical Company Limited).
NPS Pharmaceuticals, Inc.
Gail Brophy, 908-450-5335
Source: NPS Pharmaceuticals, Inc.Copyright Business Wire 2012